Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in HIV-1-Exposed Infants
NCT02778204Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of maraviroc in human immunodeficiency virus infection (HIV) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding at Week 6, Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Analysis at Week 6 and 6 more. Started Jun 2017; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02778204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778204.